Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO, PhRMA Urge Delay In Part B Drug Price Substitution Policy Until AMP Reg Finalized

This article was originally published in The Pink Sheet Daily

Executive Summary

BIO and PhRMA urge CMS to delay making reimbursement rate substitutions for Medicare Part B drugs based on comparing ASP to AMP until the agency finalizes its rules on the methodology for calculating AMP. The final AMP rule is expected in 2013.

You may also be interested in...

CMS Resists OIG Pressure To Expand Drug Price Substitution In Medicare

CMS does not concur with recommendations from the HHS Office of the Inspector General that it should apply its AMP-based price substitution more broadly for drugs reimbursed by Medicare Part B.

Medicaid AMP Final Rule Not Expected Until 2013, CMS Official Says

Pharmaceutical industry stakeholders could have to wait another year before Medicaid details how to calculate average manufacturer prices for drugs and drug rebates and how to handle other complex issues from the Affordable Care Act.

CMS’ Long-Awaited AMP Rule Seeks To Clarify Uncertainties In Affordable Care Act’s Definition

A proposed rule on the calculation of average manufacturer price issued Jan. 27 addresses numerous complex issues for the pharmaceutical industry in its 200 pages, including a proposal that manufacturers report AMP based on their actual sales to retail community pharmacies or to wholesalers for drugs distributed to retail community pharmacies.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts